Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.63
$0.4451.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.30% | 14.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.30% | 14.22% | |||
| Cost of Revenue | -11.31% | 18.71% | |||
| Gross Profit | -0.92% | 13.56% | |||
| SG&A Expenses | 30.31% | 39.41% | |||
| Depreciation & Amortization | 0.00% | 35.96% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.87% | 33.95% | |||
| Operating Income | -44.10% | -22.16% | |||
| Income Before Tax | -81.92% | 10.84% | |||
| Income Tax Expenses | -85.10% | -24.21% | |||
| Earnings from Continuing Operations | -80.72% | 34.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -80.72% | 34.29% | |||
| EBIT | -44.10% | -22.16% | |||
| EBITDA | -19.16% | 2.40% | |||
| EPS Basic | -80.55% | 35.04% | |||
| Normalized Basic EPS | -74.23% | -44.03% | |||
| EPS Diluted | -80.01% | 30.78% | |||
| Normalized Diluted EPS | -68.82% | -44.29% | |||
| Average Basic Shares Outstanding | -0.89% | -0.56% | |||
| Average Diluted Shares Outstanding | -18.12% | -0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||